Hoban B, Larance B, Gisev N, Nielsen S, Cohen M, Bruno R, Shand F, Lintzeris N, Hall W, Farrell M, Degenhardt L
National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia.
The Langton Centre, South East Sydney Local Health District (SESLHD), Drug and Alcohol Services, Surry Hills, NSW, Australia.
Int J Clin Pract. 2015 Nov;69(11):1366-76. doi: 10.1111/ijcp.12716. Epub 2015 Aug 13.
The regular use of simple analgesics in addition to opioids such as paracetamol (or acetaminophen) is recommended for persistent pain to enhance analgesia. Few studies have examined the frequency and doses of paracetamol among people with chronic non-cancer pain including use above the recommended maximum daily dose.
To assess (i) the prevalence of paracetamol use among people with chronic non-cancer pain prescribed opioids, (ii) assess the prevalence of paracetamol use above the recommended maximum daily dose and (iii) assess correlates of people who used paracetamol above the recommended maximum daily dose including: age, gender, income, education, pain severity and interference, use of paracetamol/opioid combination analgesics, total opioid dose, depression, anxiety, pain self-efficacy or comorbid substance use, among people prescribed opioids for chronic non-cancer pain.
This study draws on baseline data collected for the Pain and Opioids IN Treatment (POINT) study and utilises data from 962 interviews and medication diaries. The POINT study is national prospective cohort of people with chronic non-cancer pain prescribed opioids. Participants were recruited from randomly selected pharmacies across Australia.
Sixty-three per cent of the participants had used paracetamol in the past week (95% CI = 59.7-65.8). Among the paracetamol users 22% (95% CI = 19.3-24.6) had used paracetamol/opioid combination analgesics and 4.8% (95% CI = 3.6-6.3) had used paracetamol above the recommended maximum daily dose (i.e. > 4000 mg/day). Following binomial logistic regression (χ(2) = 25.98, df = 10, p = 0.004), people who had taken above the recommended maximum daily dose were less likely to have low income (AOR = 0.52, 95% CI = 0.27-0.99), more likely to use paracetamol/opioid combination analgesics (AOR = 2.01, 95% CI = 1.02-3.98) and more likely to take a higher opioid dose (AOR = 1.00, 95% CI = 1.00-1.01).
The majority of people with chronic non-cancer pain prescribed opioids report using paracetamol appropriately. High income, use of paracetamol/opioid combination analgesics and higher opioid dose were independently associated with paracetamol use above the recommended maximum daily dose.
对于持续性疼痛,建议在使用阿片类药物(如对乙酰氨基酚)的基础上常规使用简单镇痛药以增强镇痛效果。很少有研究调查慢性非癌性疼痛患者中对乙酰氨基酚的使用频率和剂量,包括超过推荐最大日剂量的使用情况。
评估(i)开具阿片类药物的慢性非癌性疼痛患者中使用对乙酰氨基酚的患病率,(ii)评估对乙酰氨基酚使用量超过推荐最大日剂量的患病率,以及(iii)评估对乙酰氨基酚使用量超过推荐最大日剂量的患者的相关因素,包括:年龄、性别、收入、教育程度、疼痛严重程度和干扰程度、对乙酰氨基酚/阿片类药物联合镇痛药的使用情况、阿片类药物总剂量、抑郁、焦虑、疼痛自我效能或共病物质使用情况,这些患者因慢性非癌性疼痛而开具了阿片类药物。
本研究利用了为疼痛与阿片类药物治疗(POINT)研究收集的基线数据,并使用了来自962次访谈和用药日记的数据。POINT研究是一项针对开具阿片类药物的慢性非癌性疼痛患者的全国性前瞻性队列研究。参与者从澳大利亚各地随机选择的药房招募。
63%的参与者在过去一周使用过对乙酰氨基酚(95%置信区间 = 59.7 - 65.8)。在对乙酰氨基酚使用者中,22%(95%置信区间 = 19.3 - 24.6)使用过对乙酰氨基酚/阿片类药物联合镇痛药,4.8%(95%置信区间 = 3.6 - 6.3)使用的对乙酰氨基酚超过了推荐最大日剂量(即 > 4000毫克/天)。经过二项逻辑回归分析(χ(2) = 25.98,自由度 = 10,p = 0.004),使用量超过推荐最大日剂量的患者低收入的可能性较小(比值比 = 0.52,95%置信区间 = 0.27 - 0.99),使用对乙酰氨基酚/阿片类药物联合镇痛药的可能性较大(比值比 = 2.01,95%置信区间 = 1.02 - 3.98),且服用较高阿片类药物剂量的可能性较大(比值比 = 1.00,95%置信区间 = 1.00 - 1.01)。
大多数开具阿片类药物的慢性非癌性疼痛患者报告适当使用了对乙酰氨基酚。高收入、使用对乙酰氨基酚/阿片类药物联合镇痛药和较高的阿片类药物剂量与对乙酰氨基酚使用量超过推荐最大日剂量独立相关。